BC
AKTX

Broadfin Capital’s Akari Therapeutics AKTX Stock Holding History

Broadfin Capital’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-59
Closed -$2.26M – 84
2014
Q4 		$2.26M Hold
59
– – 0.2% 70
2014
Q3 		$2.87M Hold
59
– – 0.3% 64
2014
Q2 		$2.92M Hold
59
– – 0.28% 62
2014
Q1 		$3.06M Buy
+59
New +$3.34M 0.3% 71

Other funds holding AKTX

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Broadfin Capital's AKTX Position: Q1 2015 in Review

Broadfin Capital sold out of Akari Therapeutics (AKTX) in Q1 2015, closing a stake of 59 shares — an estimated $2.26M sold.

Broadfin Capital first reported a position in AKTX in Q1 2014 and held it in 4 quarters. The position peaked at $3.06M in Q1 2014. 3 funds tracked by Wall St. Rank hold AKTX as of Q1 2015.

  • Broadfin Capital reported no remaining Akari Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Broadfin Capital sold 59 Akari Therapeutics shares in Q1 2015, an estimated $2.26M.
  • Broadfin Capital first reported a position in Akari Therapeutics in Q1 2014 and held it in 4 quarters.
  • Broadfin Capital's Akari Therapeutics position peaked at $3.06M in Q1 2014.
  • 3 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2015.

Based on Broadfin Capital's 13F filing for Q1 2015, filed 15 May 2015.